Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs),[3] and consumables with fully kitted reagents.

Standard BioTools is a public company traded on the Nasdaq stock exchange, previously under the ticker symbol FLDM,[4] currently under LAB.

The company has remained a pioneer in integrated microfluidic technology, with continued iterations of IFCs for a growing variety of applications.

Following a $250 million investment from Casdin Capital, LLC and Viking Global Investors LP in April 2022, Fluidigm changed its name to Standard BioTools.

[11] This change in name emphasized their mission to create a diversified, scalable innovation-focused life science tools company serving the pharma research markets.